DynPort Newsroom
Featured News
DynPort Vaccine: Playing Biodefense (MDBiz News)
"The plague, the flu and the terrifying-sounding, potentially cataclysmic botulinum neurotoxin — DynPort Vaccine Co. has its sights set on the lot of them." Includes a video interview with DynPort President Dr. Robert V. House.
DynPort Named to The Scientist Best Places to Work in Industry
DynPort Vaccine Company LLC, a CSC company, was named to The Scientist magazine’s Best Places to Work in Industry 2012. Ranked 9 of 20, this is DynPort’s fourth year on the list, which is celebrating its tenth year of publication.
CSC's DynPort Vaccine Company Releases Results for Phase 2 Botulinum Vaccine Clinical Trial
FALLS CHURCH, Va., Jan. 24, 2012 – CSC (NYSE: CSC) announced today that DynPort Vaccine Company LLC (DVC), a CSC company, has completed a Phase 2 clinical trial for its recombinant botulinum vaccine candidate, rBV A/B.
>DynPort press release archive
Biopharmaceutical & Government Contracting News
January 2013:The Federal market is large, but entry can be daunting due to the seemingly endless string of requirements and documentation. Learn where to start. Plus, new medical countermeasure teaming opportunities for upcoming government contracts.
>Read more newsletters or subscribe
DynPort is a wholly owned CSC subsidiary. Visit the CSC newsroom for more CSC news.
About DynPort
- Company profile (infographic: PDF, 432K)
Media Information
Video: DynPort President Dr. Robert V. House answers the question "What does DynPort do?" (1:34, YouTube).
Social Media
- Bugs and Drugs blog by DynPort President Dr. Robert V. House
- Google+
- YouTube
- Tumblr
Media Contact
Press inquiries ONLY:
Michael McGinnis, Director, New Business
+1 301.607.5004
>email
If you are not a reporter, please use this form to contact us, for the quickest response. (We promise it goes right to a real person--a few actually.)